9/11 Blood Cancer Lawyers: Leukemia, Lymphoma & Myeloma VCF Compensation

Who qualifies for 9/11 blood cancer compensation?

Anyone diagnosed with a blood cancer, including leukemia, lymphoma, or multiple myeloma, following presence in the covered 9/11 areas, at the Pentagon, or in Shanksville, Pennsylvania during the covered periods may qualify for VCF compensation. This includes area workers, residents, students, teachers, first responders, cleanup and recovery workers, volunteers, and surviving family members of those who died from a 9/11-related blood cancer.

Free medical care runs through the WTC Health Program, which covers Manhattan south of Houston Street and any block in Brooklyn within 1.5 miles of the former World Trade Center site. Compensation runs through the VCF, which covers Manhattan south of Canal Street plus routes of debris removal.

If you were between Canal and Houston Street, you may still qualify for both. Daily life in Lower Manhattan rarely stopped at Canal Street, and presence can be established with records or sworn affidavits.

Blood cancers carry the shortest minimum latency period of any cancer covered by the WTC Health Program, meaning certification and compensation claims can often move forward sooner than for other cancer types.

What types of blood cancer are covered by the WTC Health Program?

The WTC Health Program certifies malignant neoplasms of the blood, bone marrow, and lymphatic system as 9/11-related conditions. This covers the major categories of blood cancer diagnosed in the 9/11 community.

• Hodgkin lymphoma: covered in all subtypes.
• Non-Hodgkin lymphoma: covered in all subtypes, including follicular, diffuse large B-cell, T-cell, and mycosis fungoides.
• Multiple myeloma and plasma cell neoplasms: including plasma cell leukemia and plasmacytoma.
• Lymphoid leukemias: including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), hairy cell leukemia, prolymphocytic leukemia, and adult T-cell leukemia.
• Myeloid leukemias: including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), myeloid sarcoma, acute promyelocytic leukemia, and acute myelomonocytic leukemia.
• Monocytic leukemias: acute and chronic.
• Other and unspecified leukemias.

Several related myeloid conditions are also certified under the WTC Health Program's rare-cancer framework, covering any cancer occurring in fewer than 15 cases per 100,000 people per year, and they share the same 146-day latency as the conditions above.

• Myelodysplastic syndromes (MDS).
• Myeloproliferative neoplasms: including polycythemia vera, essential thrombocythemia, and myelofibrosis.
• Myelodysplastic/myeloproliferative neoplasms, and myeloid malignancies associated with eosinophilia and abnormalities of growth factor receptors.

MGUS (monoclonal gammopathy of undetermined significance) is not itself eligible for certification. Diagnostic monitoring for MGUS may be covered when there are symptoms of a plasma cell neoplasm, but MGUS alone cannot be certified.

More than 400,000 people are estimated to have been exposed to 9/11 toxins across the covered areas in New York City, the Pentagon, and Shanksville, Pennsylvania. The dust, smoke, and debris released by the collapse of the World Trade Center contained known and suspected carcinogens, including benzene, dioxins, and polycyclic aromatic hydrocarbons linked to blood and bone marrow cancers.

Benzene in particular is a well-established cause of leukemia and other blood cancers, and it was present in the fuel, plastics, and building materials that burned at the site. Studies have examined blood cancer rates in 9/11-exposed responders and survivors, with several reporting elevated incidence compared to general-population baselines.

Blood cancers do not appear immediately after exposure to a carcinogen, but they can develop faster than solid tumors. Most solid cancers require years to form, while blood cancers arise from direct toxic injury to blood-forming cells in the bone marrow, which can produce malignant changes much sooner.

Certification does not require proof that 9/11 exposure was the only cause of a particular blood cancer. Under federal law, the standard is whether the exposure was substantially likely to be a significant factor in aggravating, contributing to, or causing the condition, not whether it was the sole or exclusive cause.

Family history of blood cancer, prior chemotherapy or radiation exposure, and other established risk factors are common and generally do not prevent certification.

Blood cancer symptoms vary significantly by type and can be subtle in early stages, often overlapping with common, less serious conditions.

Common symptoms across blood cancer types

• Persistent fatigue or weakness
• Unexplained fever, night sweats, or chills
• Unexplained weight loss
• Swollen lymph nodes in the neck, underarms, or groin
• Easy bruising or bleeding
• Frequent or recurrent infections
• Bone or joint pain

Symptoms more specific to certain types

• Abdominal fullness or pain from an enlarged spleen or liver (leukemias, some lymphomas)
• Persistent cough or chest discomfort (lymphoma affecting chest lymph nodes)
• Bone pain, frequent fractures, or kidney problems (multiple myeloma)
• Skin lesions or patches (mycosis fungoides, a type of T-cell lymphoma)

Any of these symptoms in a person with 9/11 exposure history should be evaluated by a WTCHP participating specialist. The diagnosis itself can be made by any qualified physician, but certification of the cancer as being 9/11-related is made by the WTCHP.

Blood cancer has the shortest minimum latency period of any cancer covered by the WTC Health Program: 0.4 years, or 146 days, between first 9/11 exposure and first diagnosis. This latency requirement is set by the WTC Health Program and has no exceptions.

Nearly all blood cancer claimants meet this requirement easily, since 146 days is a small fraction of the time that has passed since 2001 for virtually every claimant. A blood cancer diagnosed at any point from early 2002 forward satisfies latency.

The reason blood cancer's latency is so short is biological. Leukemia and related blood cancers arise from direct toxic injury to blood-forming cells in the bone marrow, which can produce malignant changes far faster than the years-long process behind most solid tumors.

By comparison, thyroid cancer's minimum latency is 2.5 years, and most other solid cancers, including breast, lung, and prostate, use a four-year minimum. Mesothelioma has the longest latency under the program, at 11 years.

The two-year VCF registration deadline runs from the date the WTC Health Program certifies the blood cancer as 9/11-related, not from the date of diagnosis. A blood cancer diagnosed years ago remains eligible for certification and compensation review if registration is completed within the applicable two-year window.

What is the VCF payout for 9/11 blood cancer?

Certified 9/11 blood cancer qualifies claimants for free medical treatment through the WTC Health Program, and allows the claimant to submit a claim for financial compensation through the September 11th Victim Compensation Fund. The VCF's non-economic loss award for blood cancer is published in its Non-Economic Loss Awards and Certified Conditions Fact Sheet.

Baseline non-economic loss award

• Blood cancer baseline: $250,000. Leukemia, lymphoma, multiple myeloma, and other blood cancers are compensated at the statutory maximum of $250,000 for a single cancer condition, consistent with the VCF's treatment of solid cancers generally.
• Documentation supporting the baseline. The $250,000 baseline applies with medical documentation of the diagnosis and treatment. Extensive treatment burden, such as chemotherapy, radiation, stem cell transplant, or ongoing remission monitoring, supports the baseline award; advanced staging or relapse is relevant but not required to reach $250,000.

Aggregate compensation with multiple certified conditions

Non-economic loss compensation for a single cancer condition is capped at $250,000 under the VCF Act. Where a claimant has multiple certified conditions on their own record, aggregate non-economic loss may exceed the $250,000 single-condition cap.

For a claimant with two or more certified cancers, aggregate non-economic loss compensation generally reaches at least $300,000. The current VCF aggregate maximum of $340,000 is reserved for claims involving multiple certified cancers, or a certified cancer alongside another certified condition of extraordinary severity. The $340,000 aggregate is not simply the sum of baseline amounts for each condition; the VCF weighs the severity of each certified condition together in setting the total award.

Economic loss and wrongful death compensation

In addition to non-economic loss, the VCF may award economic loss for medical expenses, lost earnings, and other financial impacts from blood cancer treatment. These economic loss awards can be substantial in cases involving temporary or permanent disability due to the treatment and effects of blood cancer.

Wrongful death compensation is available to the personal representatives of individuals who died from a 9/11-related blood cancer. Attorney fees for VCF claims are capped at 10% by federal statute.

How Baione Law handles a 9/11 blood cancer claim

Baione Law represents 9/11 blood cancer claimants at every stage:

1. Free Case Review. The firm evaluates presence in the exposure zone, exposure category, blood cancer diagnosis, subtype, and current WTCHP certification status. No cost, no obligation.
2. WTC Health Program enrollment and certification support. For claimants not yet enrolled, the firm assists with enrollment and coordinates medical record submission to WTCHP providers for certification, including for less common subtypes such as hairy cell leukemia or plasma cell neoplasms.
3. VCF registration and claim filing. The firm registers the claim, files the compensation claim, and prepares supporting documentation including presence, exposure, pathology, staging, and treatment history.
4. Medical records and impact documentation. The firm compiles the medical, economic, and non-economic loss documentation the VCF requires.
5. Award, appeals, and amendments. After the VCF issues an award, the firm reviews it, files an appeal if warranted, and handles amendments for subsequent certified conditions or documented progression of the blood cancer.

Attorney fees are capped at 10% by federal statute.